EC
ADPT icon

Elequin Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Elequin Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05K Buy
+49
New +$751 ﹤0.01% 571

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Elequin Capital's ADPT Position: Q2 2026 in Review

Elequin Capital opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 49 shares worth $1.05K. The stake represents ﹤0.01% of the portfolio and ranks #571 among its holdings.

300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Elequin Capital held 49 shares of Adaptive Biotechnologies worth $1.05K as of Q2 2026.
  • Adaptive Biotechnologies was a new Elequin Capital position in Q2 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #571 holding.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.